Method for the treatment of cardiovascular fibrosis

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9594083
SERIAL NO

14426563

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
UNIVERSITE DE LORRAINE34 COURS LEOPOLD NANCY 54000
UNIVERSITE PARIS DESCARTES12 RUE DE L'ECOLE DE MÉDECINE PARIS 75006
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE101 RUE DE TOLBIAC PARIS 75013
UNIVERSITE PARIS DIDEROT PARIS-75 RUE THOMAS MANN PARIS 75013
CENTER HOSPITALIER ET UNIVERSITAIRE DE NANCY (CHU)29 AVENUE DE LATTRE DE TASSIGNY CO60034 NANCY 54035

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Farman, Nicolette Paris, FR 13 17
Jaisser, Frederic Paris, FR 15 127
Rossignol, Patrick Vandoeuvre-les-nancy, FR 7 3
Tarjus, Antoine Paris, FR 3 2
Zannad, Faiez Vandoeuvre-les-nancy, FR 7 3

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 14, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00